OptiNose (OPTN)

• Market cap: $53.4M
• 1 day: -2.39%
• 5 days: -8.76%
• 1 month: -11.35%
• 3 months: -34.77%
• 6 months: -62.82%
• Year to date: -20.75%
• 1 year: -79.77%
• 5 years: -93.46%
• 10 years: -98.14%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Employees: 132

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

33% less capital invested

Capital invested by funds: $72.7M [Q3] → $48.7M (-$24M) [Q4]

40% less funds holding

Funds holding: 65 [Q3] → 39 (-26) [Q4]

67.34% less ownership

Funds ownership: 72.18% [Q3] → 4.84% (-67.34%) [Q4]

89% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 28

97% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 35

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 220% upside
• Avg. target: $17.50 230% upside
• High target: $18 239% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Thomas Flaten 18% 1-year accuracy 2 / 11 met price target	220% upside $17	Buy Maintained	16 Jan 2025
HC Wainwright & Co. Matthew Caufield 15% 1-year accuracy 9 / 61 met price target	239% upside $18	Buy Maintained	3 Jan 2025